Melinta Therapeutics Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications
29. Juni 2017 09:56 ET
|
Melinta Therapeutics
New Haven, Conn, June 29, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, has entered into a loan and...
Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
19. Juni 2017 16:30 ET
|
Melinta Therapeutics
- Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...
Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea
05. Juni 2017 12:45 ET
|
Melinta Therapeutics
New Haven, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that an oral...
Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe
01. Juni 2017 14:42 ET
|
Melinta Therapeutics
New Haven, Conn, June 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five...
Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI
02. Mai 2017 09:38 ET
|
Melinta Therapeutics
New Haven, Conn, May 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced an upcoming...
Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design
21. April 2017 09:56 ET
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...
Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types
21. April 2017 09:37 ET
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the...
Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017
19. April 2017 14:42 ET
|
Melinta Therapeutics
New Haven, Conn, April 19, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
02. März 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid
28. Februar 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food...